Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Strategy Found to Delay Age-Related Disorders

By BiotechDaily International staff writers
Posted on 22 Nov 2011
Scientists have demonstrated that eliminating cells that accrue with age could prevent or delay the onset of age-related disorders and disabilities. The research, conducted in mouse models, provides the first evidence that these cells could contribute to aging and suggests a way to help people stay healthier as they age.

The findings were published November 2, 2011, in the journal Nature, along with an independent commentary on the discovery. “By attacking these cells and what they produce, one day we may be able to break the link between aging mechanisms and predisposition to diseases like heart disease, stroke, cancers, and dementia,” remarked coauthor James Kirkland, MD, PhD, head of the Mayo Clinic’s (Rochester, MN, USA) Robert and Arlene Kogod Center on Aging, and a professor of aging research. “There is potential for a fundamental change in the way we provide treatment for chronic diseases in older people.”

Fifty years ago, scientists discovered that cells undergo a finite number of divisions before they stop dividing. At that point, the cells reach a state called cellular senescence where they neither die nor continue to multiply. They produce factors that injure adjacent cells and cause tissue inflammation. This alternate cell fate is believed to be a mechanism to prevent runaway cell growth and the spread of cancer. The immune system sweeps out these dysfunctional cells on a regular basis, but over time becomes less effective at “keeping house.”

As a result, senescent cells accumulate with age. Whether and how these cells cause age-related diseases and dysfunction has been a major open question in the field of aging. One reason the question has been so difficult to answer is that the numbers of senescent cells are quite limited and comprise at most only 10% to 15% of cells in an elderly individual.

“Our discovery demonstrates that in our body cells are accumulating that cause these age-related disorders and discomforts,” noted senior author Jan van Deursen, PhD, a Mayo Clinic molecular biologist and professor of cellular senescence. “Therapeutic interventions to get rid of senescent cells or block their effects may represent an avenue to make us feel more vital, healthier, and allow us to stay independent for a much longer time.”

“Through their novel methodology, the researchers discovered that deletion of senescent cells in genetically engineered mice led to improvement in at least some aspects of the physiology of these animals. So, with the caveat that the study involved a mouse model displaying accelerated aging, this paper provides important insights on aging at the cellular level,” said Felipe Sierra, PhD, director of the division of aging biology, US National Institute on Aging, National Institutes of Health (Bethesda, MD, USA).

Dr. van Deursen and colleagues genetically modified mice so their senescent cells harbored a molecule called caspase 8 that was only activated in the presence of a drug that has no effect on normal cells. When the transgenic mice were exposed to this drug, caspase 8 was triggered in the senescent cells, drilling holes in the cell membrane to destroy the senescent cells specifically.

The researchers discovered that lifelong elimination of senescent cells delayed the onset of age-related disorders such as cataracts, muscle loss, and weakness. Possibly, even more significantly, they showed that taking out these cells later in life could slow the progression of already established age-related disorders.

The findings, according to the researchers, validate a role of senescent cells in the aging process and demonstrate that chemicals secreted by these cells contribute to age-related tissue dysfunction and disease.

Related Links:

Mayo Clinic



Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.